Chugai Pharmaceutical Co., Ltd. (CHGCY)
|Net Income (ttm)||2.84B|
|Ex-Dividend Date||Jun 29, 2022|
|Day's Range||12.55 - 13.01|
|52-Week Range||11.88 - 20.75|
|Price Target||16.58 (+28.8%)|
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product... [Read more...]
According to 17 analysts, the average rating for CHGCY stock is "Buy." The 12-month stock price forecast is 16.58, which is an increase of 28.83% from the latest price.